WO1998011921A3 - Method - Google Patents

Method Download PDF

Info

Publication number
WO1998011921A3
WO1998011921A3 PCT/GB1997/002072 GB9702072W WO9811921A3 WO 1998011921 A3 WO1998011921 A3 WO 1998011921A3 GB 9702072 W GB9702072 W GB 9702072W WO 9811921 A3 WO9811921 A3 WO 9811921A3
Authority
WO
WIPO (PCT)
Prior art keywords
orally
rectally
composition
human
manganese
Prior art date
Application number
PCT/GB1997/002072
Other languages
French (fr)
Other versions
WO1998011921A2 (en
Inventor
Goeran Pettersson
Klaes Golman
Anne Jacobsen
Liv-Ingrid Odegardstuen
Anne Sjersti Fahlvik
Original Assignee
Nycomed Imaging As
Golding Louise
Goeran Pettersson
Klaes Golman
Anne Jacobsen
Liv-Ingrid Odegardstuen
Fahlvik Anne Kjersti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As, Golding Louise, Goeran Pettersson, Klaes Golman, Anne Jacobsen, Liv-Ingrid Odegardstuen, Fahlvik Anne Kjersti filed Critical Nycomed Imaging As
Priority to JP10514365A priority Critical patent/JP2001500870A/en
Priority to AU37766/97A priority patent/AU3776697A/en
Priority to CA002265856A priority patent/CA2265856A1/en
Priority to EP97934621A priority patent/EP0930897A2/en
Publication of WO1998011921A2 publication Critical patent/WO1998011921A2/en
Publication of WO1998011921A3 publication Critical patent/WO1998011921A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The invention provides the use of a physiologically tolerable manganese compound or a salt thereof, substantially free from hydrophilic polymer components containing a significant amount of a Mn2+- chelating unit, in the manufacture of an enterally, e.g. orally or rectally, administrable MRI contrast medium composition for use in a method of imaging of a human or non-human animal body which has fasted for a period of at least 6, preferably at least 10, more preferably at least 12 hours before enteral administration of said composition. It has been found that diagnostically effective levels of uptake of orally or rectally administered manganese may be achieved using this method.
PCT/GB1997/002072 1996-09-23 1997-07-30 Method WO1998011921A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10514365A JP2001500870A (en) 1996-09-23 1997-07-30 Method
AU37766/97A AU3776697A (en) 1996-09-23 1997-07-30 Method
CA002265856A CA2265856A1 (en) 1996-09-23 1997-07-30 Method
EP97934621A EP0930897A2 (en) 1996-09-23 1997-07-30 Method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9619759.5 1996-09-23
GBGB9619759.5A GB9619759D0 (en) 1996-09-23 1996-09-23 Method

Publications (2)

Publication Number Publication Date
WO1998011921A2 WO1998011921A2 (en) 1998-03-26
WO1998011921A3 true WO1998011921A3 (en) 1998-08-13

Family

ID=10800328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002072 WO1998011921A2 (en) 1996-09-23 1997-07-30 Method

Country Status (7)

Country Link
EP (1) EP0930897A2 (en)
JP (1) JP2001500870A (en)
CN (1) CN1238698A (en)
AU (1) AU3776697A (en)
CA (1) CA2265856A1 (en)
GB (1) GB9619759D0 (en)
WO (1) WO1998011921A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999613B (en) * 2015-09-30 2020-11-17 杜克大学 Ascorbic acid formulations as contrast agents and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308983A2 (en) * 1987-09-25 1989-03-29 Salutar, Inc. NMR imaging with Mn(II) coordination compositions
WO1993010821A1 (en) * 1991-11-29 1993-06-10 Bracco S.P.A. A method and formulations useful to improve the study of human body cavities
EP0556842A2 (en) * 1992-02-20 1993-08-25 Meiji Milk Products Company Limited Contrasting composition for MRI of the gastrointestinal tract
WO1993021960A1 (en) * 1992-04-24 1993-11-11 Nycomed Imaging As Nhr contrast agents
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
WO1997002842A1 (en) * 1995-07-11 1997-01-30 Thomsen Henrik S Mr contrast agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308983A2 (en) * 1987-09-25 1989-03-29 Salutar, Inc. NMR imaging with Mn(II) coordination compositions
WO1993010821A1 (en) * 1991-11-29 1993-06-10 Bracco S.P.A. A method and formulations useful to improve the study of human body cavities
EP0556842A2 (en) * 1992-02-20 1993-08-25 Meiji Milk Products Company Limited Contrasting composition for MRI of the gastrointestinal tract
WO1993021960A1 (en) * 1992-04-24 1993-11-11 Nycomed Imaging As Nhr contrast agents
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
WO1997002842A1 (en) * 1995-07-11 1997-01-30 Thomsen Henrik S Mr contrast agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D'AGINCOURT L: "MRI AGENTS FOR ABDOMEN OFFER HIGH SENSITIVITY", DIAGNOSTIC IMAGING INTERNATIONAL, vol. 8, no. 6, 1 September 1992 (1992-09-01), pages 42 - 43, 45, 47 - 50, XP000321789 *
RUBIN D L ET AL: "FORMULATION OF RADIOGRAPHICALLY DETECTABLE GASTROINTESTINAL CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING: EFFECTS OF A BARIUM SULFATE ADDITIVE ON MR CONTRAST AGENT EFFECTIVENESS", MAGNETIC RESONANCE IN MEDICINE, vol. 23, no. 1, 1 January 1992 (1992-01-01), pages 154 - 165, XP000250035 *

Also Published As

Publication number Publication date
GB9619759D0 (en) 1996-11-06
WO1998011921A2 (en) 1998-03-26
EP0930897A2 (en) 1999-07-28
JP2001500870A (en) 2001-01-23
CN1238698A (en) 1999-12-15
AU3776697A (en) 1998-04-14
CA2265856A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
MX9504034A (en) Medical administering forms containing tioctic acid, or tioctic acid solid salts having improved release and bioavailability.
HK1019699A1 (en) Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
EP0808324A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
CA2303426A1 (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
IL116847A0 (en) Diagnostic imaging contrast agents and methods for extending the blood retention thereof
HUP0100159A3 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO1997049736A3 (en) Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
WO1991010645A3 (en) Chelants
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
HUP0103454A2 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
HUP9900426A3 (en) Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
PT965351E (en) COMPOSITION FOR DIETETIC FOODS AND DIETETIC METHOD USING THIS TYPE OF COMPOSITION
AU2001239544A1 (en) Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
WO1998011921A3 (en) Method
CA2254144A1 (en) Pharmaceutical compositions based on diclofenac
WO1997036617A3 (en) Method of t1-weighted magnetic resonance imaging of res organs
AU3091997A (en) Composition for producing a long-lasting satiation effect
AU2823795A (en) 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
WO1998011922A3 (en) Method
WO2005030265A3 (en) Optical imaging of endometriosis
EP2060273A3 (en) MRI contrast medium composition for oral administration
CA2271735A1 (en) Magnetic resonance blood pool agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180009.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

ENP Entry into the national phase

Ref document number: 1998 78814

Country of ref document: US

Date of ref document: 19980514

Kind code of ref document: A

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2265856

Country of ref document: CA

Ref document number: 2265856

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997934621

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 514365

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997934621

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997934621

Country of ref document: EP